Adventia Pharma reinforces its strategy for patient care by signing an alliance with SECO (Spanish Society for the Surgery of Obesity and Metabolic Diseases) during 2021.

It is a non-profit Scientific Society that was founded in 1997 by a group of Spanish Surgeons with special interest in the surgical treatment of severe obesity and metabolic diseases.

Since the launch of Barimix in June 2019, Adventia has continued working on the development of products for bariatric surgery patients to expand the range of products in the formulary aimed at this therapeutic area. The alliance with SECO reinforces and consolidates our commitment to bariatric surgery and to improve the quality of life of these patients.